Naklofen (Diclofenac Sodium)

Diclofenac sodium, the active ingredient in Naklofen, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injection for intramuscular use. It treats pain and inflammation associated with postoperative recovery, musculoskeletal injuries, rheumatoid arthritis flares, and dental procedures in adult patients.

GNH USA supplies Naklofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac sodium is an NSAID that reduces inflammation and pain in several clinical settings.

- Postoperative pain: provides analgesia and reduces inflammation after surgical procedures. - Acute musculoskeletal pain: alleviates pain and swelling caused by sprains, strains or trauma. - Rheumatoid arthritis flare: diminishes joint pain and swelling during acute disease exacerbations. - Dental pain: controls pain and inflammation following dental extractions or procedures.

Common Side Effects: - Injection site pain or erythema. - Gastrointestinal discomfort such as dyspepsia. - Headache. - Dizziness.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe skin reactions, including Stevens‑Johnson syndrome. - Acute renal impairment or worsening of chronic kidney disease.

When using Naklofen, consider the following precautions: - Assess renal function: avoid in patients with severe renal impairment. - Monitor hepatic function: use cautiously in liver disease. - Avoid in known hypersensitivity to diclofenac or other NSAIDs. - Use with caution when combined with anticoagulants or antiplatelet agents. - Evaluate cardiovascular risk: limit use in patients with established heart disease. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Diclofenac sodium may interact with several medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Corticosteroids: heightened risk of ulceration and bleeding.

Moderate Interactions (Monitor Closely):\n- Diuretics: possible reduction in renal perfusion. - Lithium: increased lithium serum levels. - Methotrexate: reduced clearance leading to toxicity. - Selective serotonin reuptake inhibitors (SSRIs): enhanced bleeding tendency.